BR112012011268A2 - anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos - Google Patents
anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticosInfo
- Publication number
- BR112012011268A2 BR112012011268A2 BR112012011268A BR112012011268A BR112012011268A2 BR 112012011268 A2 BR112012011268 A2 BR 112012011268A2 BR 112012011268 A BR112012011268 A BR 112012011268A BR 112012011268 A BR112012011268 A BR 112012011268A BR 112012011268 A2 BR112012011268 A2 BR 112012011268A2
- Authority
- BR
- Brazil
- Prior art keywords
- integrin antibodies
- nanoparticle
- chemotherapeutic agents
- loaded
- linked anti
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nanotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos. a presente invenção refere-se a anticorpos anti-integrina que são covalentemente ligados a nanopartículas, em que essas nanopartículas foram antes carregadas com agentes quimioterapêuticos/citotóxicos. os conjugados anticorpo-agente quimioterapêutico-nanopartícula de acordo com a invenção, especialmente em que o anticorpo é mab di17e6 e o agente citotoóxico é doxorrubicina, mostram um aumento significante de toxidez de célula de tumor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09014206 | 2009-11-13 | ||
PCT/EP2010/006443 WO2011057709A1 (en) | 2009-11-13 | 2010-10-21 | Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012011268A2 true BR112012011268A2 (pt) | 2019-09-24 |
Family
ID=43264724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012011268A BR112012011268A2 (pt) | 2009-11-13 | 2010-10-21 | anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos |
Country Status (12)
Country | Link |
---|---|
US (1) | US20120263739A1 (pt) |
EP (1) | EP2498821A1 (pt) |
JP (1) | JP2013510804A (pt) |
KR (1) | KR20120106952A (pt) |
CN (1) | CN102665769A (pt) |
AU (1) | AU2010318323A1 (pt) |
BR (1) | BR112012011268A2 (pt) |
CA (1) | CA2780773A1 (pt) |
EA (1) | EA201270620A1 (pt) |
IL (1) | IL219523A0 (pt) |
MX (1) | MX2012005423A (pt) |
WO (1) | WO2011057709A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2672994T (lt) | 2011-02-11 | 2018-07-25 | Merck Patent Gmbh | Anti-alfa-v integrino antikūnas, skirtas prostatos vėžio gydymui |
PL2707030T3 (pl) | 2011-05-09 | 2020-08-24 | Mayo Foundation For Medical Education And Research | Metody leczenia raka |
JP6035716B2 (ja) * | 2011-08-26 | 2016-11-30 | ソニー株式会社 | 情報処理システム及び情報処理方法 |
US9675715B2 (en) | 2012-07-20 | 2017-06-13 | Canon Kabushiki Kaisha | Contrast agent for photoacoustic imaging |
JP6177036B2 (ja) * | 2012-07-20 | 2017-08-09 | キヤノン株式会社 | 光音響イメージング用造影剤 |
ES2899643T3 (es) | 2012-10-01 | 2022-03-14 | Mayo Found Medical Education & Res | Tratamientos para el cáncer |
CN103044437B (zh) * | 2012-12-21 | 2015-08-26 | 上海交通大学 | 用于***的两亲性缀合物纳米颗粒及制备方法、应用 |
WO2014143383A1 (en) | 2013-03-13 | 2014-09-18 | Agilent Technologies, Inc. | Transposome tethered to a gene delivery vehicle |
EA201692502A1 (ru) | 2014-06-16 | 2017-09-29 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Лечение миелом |
CN104434808A (zh) | 2014-07-03 | 2015-03-25 | 石药集团中奇制药技术(石家庄)有限公司 | 一种治疗性纳米粒子及其制备方法 |
US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體-抗體組合物及其製造及使用方法 |
TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
CN105288639A (zh) * | 2015-11-23 | 2016-02-03 | 中国药科大学 | 一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用 |
WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
WO2017139698A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
US11305020B2 (en) | 2016-03-21 | 2022-04-19 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
AU2017238118A1 (en) * | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
RU2019109209A (ru) | 2016-09-01 | 2020-10-05 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Способ и композиции для направленного на мишень воздействия при лечении т-клеточных видов рака |
CN109890419A (zh) | 2016-09-01 | 2019-06-14 | 梅约医学教育与研究基金会 | 用于治疗癌症的载体-pd-l1结合剂组合物 |
RU2019110071A (ru) | 2016-09-06 | 2020-10-08 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Способы лечения злокачественных новообразований, экспрессирующих pd-l1 |
WO2018048958A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
WO2018071399A1 (en) * | 2016-10-10 | 2018-04-19 | Abraxis Bioscience, Llc | Nanoparticle formulations and methods of making and using thereof |
CN109490526A (zh) * | 2017-09-13 | 2019-03-19 | 南京东纳生物科技有限公司 | 一种抗体取向修饰的荧光微球探针的制备方法及在免疫层析中的应用 |
CN107857800B (zh) * | 2017-11-09 | 2020-05-05 | 北京赛升药业股份有限公司 | 一种长效整合素抑制剂及其应用 |
CN108837299B (zh) * | 2018-07-18 | 2020-08-07 | 武汉大学 | 一种智能调节血糖的微针贴片及其制备方法 |
CN113546087B (zh) * | 2021-07-01 | 2022-11-25 | 东华大学 | 一种纤连蛋白包覆的单宁酸/铁配合物的载药纳米材料及其制备和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE244306T1 (de) | 1994-12-20 | 2003-07-15 | Merck Patent Gmbh | Monoklonaler antikörper gegen das alpha-v- integrin |
US20070025889A1 (en) * | 2005-07-28 | 2007-02-01 | Pcbu Business Services, Inc. | Reactors, reactor assemblies and production processes |
DE102005062440B4 (de) * | 2005-12-27 | 2011-02-24 | Lts Lohmann Therapie-Systeme Ag | Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen |
US8715718B2 (en) * | 2006-07-14 | 2014-05-06 | Rutgers, The State University Of New Jersey | Extracellular matrix production from nanoscale substrate |
US20110177155A1 (en) * | 2007-08-21 | 2011-07-21 | Immune Disease Institute, Inc. | Methods of delivery of agents to leukocytes and endothelial cells |
-
2010
- 2010-10-21 EA EA201270620A patent/EA201270620A1/ru unknown
- 2010-10-21 CA CA2780773A patent/CA2780773A1/en not_active Abandoned
- 2010-10-21 AU AU2010318323A patent/AU2010318323A1/en not_active Abandoned
- 2010-10-21 US US13/509,492 patent/US20120263739A1/en not_active Abandoned
- 2010-10-21 CN CN2010800511721A patent/CN102665769A/zh active Pending
- 2010-10-21 EP EP10768699A patent/EP2498821A1/en not_active Withdrawn
- 2010-10-21 JP JP2012538212A patent/JP2013510804A/ja active Pending
- 2010-10-21 BR BR112012011268A patent/BR112012011268A2/pt not_active IP Right Cessation
- 2010-10-21 MX MX2012005423A patent/MX2012005423A/es unknown
- 2010-10-21 KR KR1020127015197A patent/KR20120106952A/ko not_active Application Discontinuation
- 2010-10-21 WO PCT/EP2010/006443 patent/WO2011057709A1/en active Application Filing
-
2012
- 2012-05-01 IL IL219523A patent/IL219523A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20120263739A1 (en) | 2012-10-18 |
KR20120106952A (ko) | 2012-09-27 |
CN102665769A (zh) | 2012-09-12 |
EA201270620A1 (ru) | 2012-12-28 |
CA2780773A1 (en) | 2011-05-19 |
JP2013510804A (ja) | 2013-03-28 |
WO2011057709A1 (en) | 2011-05-19 |
AU2010318323A1 (en) | 2012-06-28 |
IL219523A0 (en) | 2012-06-28 |
EP2498821A1 (en) | 2012-09-19 |
MX2012005423A (es) | 2012-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012011268A2 (pt) | anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos | |
BR112012024564A2 (pt) | anticorpos contra csf-1r | |
NZ595574A (en) | Anti-fcrh5 antibodies and immunoconjugates and methods of use | |
BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
WO2008045976A3 (en) | Compositions and methods for treating and diagnosing cancers | |
MX2015001399A (es) | Anticuerpos anti-etbr e inmunoconjugados. | |
NZ731633A (en) | Antibodies against cd73 and uses thereof | |
MX2013003452A (es) | Conjugados de amatoxina con enlazantes mejorados. | |
AR080795A1 (es) | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) | |
MX2010005830A (es) | Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo. | |
EA201270654A1 (ru) | Моноклональные антитела, связывающие b7h6, и их применение | |
NZ710746A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
GEP20196956B (en) | Anti-gcc antibody molecules and related compositions and methods | |
WO2015054691A8 (en) | Tem8 antibodies and their use | |
BR112012012887A2 (pt) | minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito. | |
NZ596834A (en) | Prlr-specific antibody and uses thereof | |
UA108598C2 (xx) | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
EA201691963A1 (ru) | Производные тубулизина | |
NZ596490A (en) | Monoclonal antibodies that bind GT468 for the treatment of cancer | |
AR077866A1 (es) | Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina | |
TR201903026T4 (tr) | S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari. | |
MY150246A (en) | Alpha 5 - beta 1 antibodies and their uses | |
EP2519542A4 (en) | ANTI-CDH3 ANTIBODY AND ITS USE | |
CL2008003525A1 (es) | Conjugado de anticuerpo monoclonal humano anti-rg1 o una porcion de union a antigeno del mismo con moleculas asociadas, composicion que lo comprende; metodo in vitro para inhibir el crecimiento de una celula tumoral que expresa rg-1; uso de dicho conjugado para tratar el cancer | |
EA201690321A1 (ru) | Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |